Chris Twelves Selected Research

(N-methyl) erythromycin

8/2014

Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chris Twelves Research Topics

Disease

50	Breast Neoplasms (Breast Cancer) 08/2022 - 01/2002
37	Neoplasms (Cancer) 11/2021 - 01/2002
9	Colonic Neoplasms (Colon Cancer) 04/2016 - 05/2002
8	Neoplasm Metastasis (Metastasis) 08/2022 - 10/2004
6	Disease Progression 08/2022 - 01/2002
5	Brain Neoplasms (Brain Tumor) 01/2022 - 01/2017
5	Fatigue 01/2022 - 09/2003
5	Neutropenia 01/2016 - 06/2004
4	Sepsis (Septicemia) 01/2020 - 06/2002
4	Colorectal Neoplasms (Colorectal Cancer) 01/2017 - 06/2004
3	Diarrhea 01/2019 - 12/2014
3	Alopecia (Baldness) 12/2015 - 09/2003
2	COVID-19 01/2022 - 01/2020
2	Infections 01/2022 - 01/2020
2	Pain (Aches) 01/2022 - 04/2010
2	Pneumonia (Pneumonitis) 01/2022 - 11/2015
2	Glioblastoma (Glioblastoma Multiforme) 11/2021 - 01/2021
2	Vomiting 01/2020 - 12/2015
2	Acute Kidney Injury (Acute Renal Failure) 01/2020 - 11/2015
2	Nausea 12/2015 - 12/2014
2	Hypersensitivity (Allergy) 11/2014 - 03/2013
1	Bone Diseases (Bone Disease) 08/2022
1	Glioma (Gliomas) 11/2021
1	Triple Negative Breast Neoplasms 11/2021
1	Inflammation (Inflammations) 01/2020
1	Exanthema (Rash) 01/2020
1	Hypertension (High Blood Pressure) 01/2020
1	Unconsciousness (Loss of Consciousness) 01/2020
1	Circulating Neoplastic Cells 01/2018

Drug/Important Bio-Agent (IBA)

23	Capecitabine (Xeloda)FDA Link 08/2022 - 01/2002
15	AnthracyclinesIBA 07/2019 - 01/2002
14	eribulin FDA Link 01/2020 - 04/2010
11	taxaneIBA 07/2019 - 01/2002
8	Pharmaceutical PreparationsIBA 09/2019 - 07/2004
8	Docetaxel (Taxotere)FDA Link 09/2017 - 01/2002
8	Fluorouracil (Carac)FDA LinkGeneric 01/2017 - 03/2002
7	etirinotecan pegolIBA 01/2022 - 11/2015
5	Biological ProductsIBA 01/2020 - 10/2007
5	Paclitaxel (Taxol)FDA LinkGeneric 09/2017 - 01/2002
5	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2017 - 06/2004
4	Leucovorin (Folinic Acid)FDA Link 12/2014 - 05/2002
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2009 - 01/2002
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2013
3	Hormones (Hormone)IBA 01/2022 - 01/2018
3	Topoisomerase I InhibitorsIBA 01/2018 - 07/2004
3	Epirubicin (Ellence)FDA LinkGeneric 01/2017 - 06/2004
2	CarbonIBA 08/2022 - 01/2020
2	Radium-223IBA 08/2022 - 01/2020
2	Aromatase InhibitorsIBA 01/2022 - 01/2020
2	pertuzumabIBA 01/2022 - 01/2019
2	capivasertibIBA 01/2022 - 01/2020
2	Fulvestrant (Faslodex)FDA Link 01/2022 - 01/2020
2	Antineoplastic Agents (Antineoplastics)IBA 11/2021 - 01/2021
2	CannabinoidsIBA 11/2021 - 01/2021
2	Estrogen ReceptorsIBA 02/2018 - 01/2016
2	human ERBB2 proteinIBA 02/2018 - 01/2016
2	Vinorelbine (Navelbine)FDA LinkGeneric 09/2017 - 01/2002
2	Tamoxifen FDA LinkGeneric 05/2016 - 02/2009
2	Sodium Glutamate (Accent)IBA 12/2014 - 10/2013
2	EnzymesIBA 11/2014 - 05/2002
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 08/2014 - 02/2008
2	XELOXIBA 05/2008 - 06/2004
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2007 - 07/2004
2	diflomotecanIBA 07/2004 - 09/2003
2	thiamine triphosphorate (TTP)IBA 06/2004 - 06/2002
2	doxifluridineIBA 05/2002 - 03/2002
2	Thymidine PhosphorylaseIBA 05/2002 - 01/2002
1	Collagen Type I (Type I Collagen)IBA 08/2022
1	collagen type I trimeric cross-linked peptideIBA 08/2022
1	RadiopharmaceuticalsIBA 08/2022
1	ErbB Receptors (EGF Receptor)IBA 01/2022
1	BNT162 VaccineIBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	VaccinesIBA 01/2022
1	2019-nCoV Vaccine mRNA-1273IBA 01/2022
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 11/2021
1	CannabidiolIBA 11/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	Temozolomide (Temodar)FDA LinkGeneric 01/2021
1	nabiximols (Sativex)IBA 01/2021
1	Epidermal Growth Factor (EGF)IBA 01/2020
1	xentuzumabIBA 01/2020
1	N- ((5- bromo- 2- thienyl)sulfonyl)- 2,4- dichlorobenzamideIBA 01/2018
1	Trastuzumab (Herceptin)FDA Link 01/2018
1	Sulfaphenazole FDA Link 01/2018
1	Tolbutamide (Orinase)FDA LinkGeneric 01/2018
1	Biosimilar PharmaceuticalsIBA 01/2018
1	ixabepilone (BMS 247550)FDA Link 09/2017
1	130-nm albumin-bound paclitaxelIBA 09/2017
1	PolymersIBA 09/2017
1	Gemcitabine FDA Link 09/2017
1	Insulin-Like PeptidesIBA 05/2016
1	Insulin-Like Growth Factor Binding ProteinsIBA 05/2016
1	Insulin-Like Growth Factor Binding Protein 2IBA 05/2016

Therapy/Procedure

19	Therapeutics 01/2022 - 01/2002
15	Drug Therapy (Chemotherapy) 01/2022 - 01/2002
3	Adjuvant Chemotherapy 04/2016 - 05/2009
2	Immunotherapy 11/2021 - 01/2009
1	Aftercare (After-Treatment) 01/2018